Literature DB >> 16351998

Prophylactic intravenous mannitol and normal saline in patients with poor renal function prior to cardiac surgery: time for a multicentre trial?

J M Alvarez1, C Chatwin, C Fahrer.   

Abstract

BACKGROUND: Postoperative acute renal failure requiring dialysis has a poor prognosis, which has remained unaltered for 50 years. Therefore, in cardiac surgical patients at increased risk of postoperative oliguric acute renal failure (preoperative serum creatinine >0.13 mmol/L), we assessed the use of prophylactic intravenous (i.v) 20% mannitol and normal saline therapy in addition to traditional methods of therapeutic renal support.
METHODS: Seventy-five patients with a mean preoperative serum creatinine of 0.192 mmol/L received i.v. 20% mannitol and normal saline pre-, intra- and postoperatively. This treatment was continued postoperatively until serum creatinine returned to baseline.
RESULTS: No patient required dialysis, no patient died, developed a myocardial infarction nor a stroke in the first 30 days post-surgery. Serum creatinine and urea increased to a mean peak on day 3 of 0.233 +/- 94 and 24.6 +/- 13 mmol/L, respectively. However, all patients maintained a high urine output (>2 L/day) and no patient required haemodialysis.
CONCLUSION: Therapy with i.v. 20% mannitol and normal saline appears safe and effective in maintaining a diuresis and may avoid the need for dialysis. A randomised controlled trial of this treatment in patients at increased risk of postoperative acute renal failure is warranted.

Entities:  

Year:  2000        PMID: 16351998     DOI: 10.1046/j.1444-2892.2000.00029.x

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  1 in total

1.  Differences in metabolomic profiles of male db/db and s/s, leptin receptor mutant mice.

Authors:  Nadia Saadat; Heidi B IglayReger; Martin G Myers; Peter Bodary; Smiti V Gupta
Journal:  Physiol Genomics       Date:  2012-02-07       Impact factor: 3.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.